PIK3CD and prostate cancer: Consequently, BET inhibitors inhibited the activation of AKT, mTOR, and MYC due to PI3K inhibition, and combined PI3K-BET inhibition sustained PI3K pathway inhibition and enhanced tumour cell killing in a variety of tumour models, including prostate cancer, melanoma and TNBC[71].